Your browser is old and is not supported. Upgrade for better security.
Wefunder logo

Invest in Pace Diagnostics

Revolutionary point-of-care, affordable early detection Lung cancer and Tuberculosis diagnostics

EARLY BIRD TERMS: $31,125 LEFT

$168,875

raised from 120 investors
INVESTMENT TERMS
 $20M  $18M valuation cap Future Equity
Early Bird Bonus: The first $200K of investments will be in a SAFE with a $18M valuation cap and 20% discount
$500, $1K, $5K, $20K
LEAD INVESTOR
I have learnt that Pace Diagnostics and their team have worked for many years to develop their comprehensive portfolio of point-of-care rapid diagnostics that can provide quick result with simple steps, minimally invasive, and no expert/lab dependent. Since the tests are affordable and accessible, we can use them for mass population testing, therefore, more people can be tested and save lives. Pace Diagnostics are passionate about their science, their innovative products, their saving lives mission, and their investors. I am especially attracted to their positive social impact goal – save millions of lives, at the same time, I am impressed with the enormous financial opportunity for their investors – these are billions USD market sizes for TB and Lung Cancer diagnostics. It is great news for the investors who are enthusiastic about helping others and concurrently, receive positive financial upside.
Pitch Video
Investor Panel

Highlights

1
Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF
2
Huge markets and financial opportunities: 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022
3
Our products - low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests
4
Our CE Mark is targeted for 2023, allowing product distribution in EU countries; clear path to FDA clinical trials
5
We have a portfolio of proprietary material, filed patents and licensed IPs
6
Each year: 10 million new TB infections & 2 million deaths; 2.1 million new Lung Cancer cases & 2 million new deaths
7
Our TB test is specifically developed to meet all WHO requirements for performance, cost and use
8
British Biocell International (BBI) is our manufacturing partner

Our Team

10 M tuberculosis infections w/ 2 M deaths yearly. 130 M yearly tests are needed (WHO) 1 billion smokers globally. 15% of smokers get lung cancer. Non-smoker can get lung cancer. Millions people go untested due to lack of affordable medical technology to support large-scale testing. We can meet this need w/ our patented breakthrough technology

Pitch

Overview